Overview of Kineret

What is Kineret? A Foundational Overview

Kineret is the brand name for the prescription medicine Anakinra, a highly targeted biological product used to address inflammatory conditions. It is specifically designed to interfere with a key signaling protein in the immune system to help reduce chronic, uncontrolled inflammation.

Property	Description
Active ingredient	Anakinra (recombinant IL-1 receptor antagonist)
Form	Solution for injection (single-use prefilled syringe)
Pharmacological class	IL-1 Inhibitor, Biologic Disease-Modifying Antirheumatic Drug (bDMARD)
Common use	Modulating severe systemic and autoinflammatory responses
Origin	Recombinant protein manufactured by Swedish Orphan Biovitrum AB

What Type of Medicine is Kineret (Anakinra)?

Kineret is the trade name for the substance Anakinra, which is classified as an Interleukin-1 (IL-1) Inhibitor and belongs to the broader category of Biologic Disease-Modifying Antirheumatic Drugs (bDMARDs). As a differentiating feature, Anakinra is the only IL-1 receptor antagonist approved for certain ultra-rare autoinflammatory conditions like Neonatal-Onset Multisystem Inflammatory Disease (NOMID). The drug itself is a recombinant protein—a man-made version of a naturally occurring human protein called the IL-1 receptor antagonist (IL-1Ra). This origin confirms its identity as a targeted biologic agent that is structurally similar to the body's own regulatory molecules, supporting its use where endogenous regulation is insufficient.

Composition, Form, and General Purpose

The active component, Anakinra, is provided as a sterile, clear, preservative-free solution for injection in a prefilled syringe intended for subcutaneous administration (injection under the skin). The product is manufactured by Swedish Orphan Biovitrum AB and is strictly an Rx-only (prescription-only) medicine in major markets. The general purpose of this medication is to help reduce excessive and inappropriate systemic inflammation that is driven by the IL-1 cytokine. It acts as a competitive receptor antagonist by binding to the IL-1 receptor, thereby blocking the inflammatory messenger from completing its signaling pathway, which helps to dampen the associated inflammatory response. Pharmacological studies confirm that, as an interleukin-1 receptor antagonist, Anakinra effectively mediates joint protection and reduces local tissue damage. This indicates the medicine offers a focused approach clinically recognized for controlling uncontrolled, IL-1-mediated inflammation.

Regulatory References

Kineret EMA EPAR

What side effects are possible with Kineret?

Possible Side Effects and Safety Information

Kineret (anakinra) has a documented safety profile established through clinical trials and regulatory surveillance, categorized by the frequency and organ system affected, consistent with the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Frequency-Classified Adverse Reactions

The most commonly reported side effects fall into the Very Common and Common categories:

Classification	Examples of Reactions
Very Common (ge 1/10)	Injection site reactions (erythema, pain, swelling); Headache (in certain populations)
Common (ge 1/100 to < 1/10)	Serious infections, Neutropenia (low neutrophil count), Upper respiratory tract infection, Nausea, Abdominal pain
Uncommon (ge 1/1000)	Hypersensitivity reactions (e.g., urticaria, angioedema)
Rare (< 1/1000)	Anaphylactic reaction, Thrombocytopenia, DRESS, Non-infectious hepatitis

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources include Serious Infections (e.g., bacterial, fungal), Serious Hypersensitivity Reactions (including anaphylaxis), and clinically significant Neutropenia.

Official labeling defines specific restrictions. Kineret is contraindicated in individuals with a known hypersensitivity to the drug substance, any excipient, or proteins derived from E. coli. Treatment should not be initiated in patients who have an active infection or existing neutropenia ( ANC < 1.5 imes 10^9/ l). Co-administration with Tumor Necrosis Factor (TNF)-blocking agents is not recommended due to an increased risk of serious infection and neutropenia.

Some safety patterns are related to duration: Injection site reactions are often most pronounced at the beginning of treatment and typically lessen over time. Caution is noted for the older adult population due to a generally higher incidence of infections.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation provides specific guidance on overdose, which is based on clinical trial data and supratherapeutic exposure studies. This information is critical for understanding the documented risks and required emergency actions.

Overdose Scope

Domain	Content based on Official Regulatory Documentation
Documented overdose presentations	No dose-limiting toxicities specific to Kineret (anakinra) were observed in clinical trials. The adverse event profile following administration of supratherapeutic doses showed no overall difference from that seen in standard therapeutic studies.
Dose-related or exposure-related factors	The absence of unique toxicity was established following the administration of doses up to 2 mg/kg/hour over a 72-hour treatment period in certain clinical studies.
Emergency-response statements	The official overdose section does not list specific mandatory immediate actions or procedural instructions (e.g., specific antidote administration).
When immediate medical help is required	Seek immediate medical attention for any suspected overdose event or resulting systemic distress.

Overdose Classifications (High-Level)

Domain	Content based on Official Regulatory Documentation
Severity classification	Acute overdose is generally classified as non-toxic; no specific severe manifestations unique to an overdose event are documented.
Overdose-context constraints	No specific antidote for Kineret is documented in the prescribing information. Management is considered symptomatic and supportive.

Connection to the overall overdose profile:

Regulatory documents define the Kineret overdose profile primarily by the absence of a unique, acute toxicity syndrome, even after exposure to doses significantly higher than recommended. This finding means that the mandated guidance focuses on the standard clinical procedure to seek immediate medical attention for assessment and supportive care, as there is no specific antidote or specialized procedural protocol required in the official labeling.

Therapeutic Uses of Kineret

What Kineret Treats: Main Uses and Benefits

A prescription medicine, Kineret (anakinra) may be relevant for managing specific inflammatory conditions, helping to ease pronounced and challenging symptoms that interfere with daily stability.

Controlling Systemic Autoinflammatory Diseases

Kineret is commonly used across conditions presenting with episodic or chronic systemic inflammation, particularly the ultra-rare Cryopyrin-Associated Periodic Syndromes (CAPS), including NOMID, and Deficiency of IL-1 Receptor Antagonist (DIRA). It is also commonly used in the management of Familial Mediterranean Fever (FMF) and Still's Disease (SJIA/AOSD). It is applied in situations involving certain distressing symptoms that appear suddenly or intensify over time, such as persistent, high spiking fevers, inflammatory rashes, and severe joint pain. This support is considered relevant by helping to support clinical stability and may assist in reducing the risk of functional organ stress, such as central nervous system or hearing impairment, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“Kineret is considered relevant across domains where additional symptomatic support is needed, particularly when systemic inflammation is the core problem.”

Managing Active Rheumatoid and Still’s Disease

The medicine is relevant in clinical settings marked by heightened distress from severe Rheumatoid Arthritis (RA) in adults who have had an inadequate response to prior therapies. It is also commonly used in managing the systemic inflammation and arthritis associated with Still’s Disease in both children (SJIA) and adults (AOSD). Kineret is relevant for easing pronounced symptoms like debilitating joint swelling, pain, and stiffness. By addressing these symptoms, it contributes to the patient's improved day-to-day comfort during periods of heightened symptoms and offers a long-term therapeutic benefit that may play a role in managing joint structural changes.

The medicine is commonly used to help with conditions such as Rheumatoid Arthritis (RA), SJIA, AOSD, CAPS (MWS, FCAS, NOMID), FMF, and DIRA.

Quick Facts: Therapeutic Focus

Primary Therapeutic Domains	Conditions presenting with systemic or localized discomfort, including autoinflammatory syndromes and active rheumatoid disease.
Key Symptom Areas	Helps address symptom clusters related to physical discomfort (joint pain, swelling) and systemic imbalance (spiking fevers, rash).
Patient Benefit Focus	Supports general well-being during symptomatic phases and assists with maintaining functional stability.

Regulatory References

European Medicines Agency summary on Kineret

Eligibility and Restrictions for Use

Kineret (anakinra) eligibility is strictly defined by specific population criteria documented in official regulatory labeling. Use is contraindicated in patients with a known hypersensitivity to the active ingredient anakinra or to E. coli-derived proteins. Treatment must also not be initiated in patients with an active infection or a state of neutropenia (low white blood cell count).

Population Status	Eligibility Rule
Approved Age Groups	Adults ge 18 years for Rheumatoid Arthritis (RA). For CAPS and Still's Disease (SJIA/AOSD), approved for infants ge 8 months and ge 10 kg.
Age Limitations	Efficacy in children with Juvenile Rheumatoid Arthritis (JIA) is not established. Caution is advised when treating the elderly population (ge 65 years).
Organ Function	Patients with severe renal impairment (CLcr < 30 mL/min) require conditional use, potentially involving administration on an every-other-day schedule.
Reproductive Health	Use is not recommended during pregnancy. Breast-feeding should be discontinued during treatment.

This tiered structure clarifies which populations are explicitly prohibited and which require specific, label-based consideration before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Kineret (anakinra) based on pharmacodynamic constraints and pharmacokinetic considerations regarding drug clearance.

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Live vaccines; Tumor Necrosis Factor (TNF) blocking agents (e.g., etanercept).
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction; Pharmacokinetic consideration (renal clearance).
Timing-based interaction rules (if applicable)	No mandatory separation windows are documented for non-prohibited medicinal products.
Interaction-related restrictions	Co-administration with live vaccines is restricted; Use in combination with TNF blocking agents is not recommended.

Official Interaction Statements

The co-administration of Kineret with live vaccines is restricted by regulatory authorities. The combination of Kineret with TNF blocking agents is officially not recommended due to an observed increased incidence of serious infections and neutropenia.

Regulatory information explicitly notes that no formal studies have been conducted or observed for interaction patterns with other common drug classes, including those affecting CYP450 enzymes or drug transporters.

Population-Specific Interaction Notes

Kineret is substantially cleared by the kidney, which represents a pharmacokinetic consideration. The mean plasma clearance is documented to be reduced by 70%–75% in individuals with severe or end-stage renal disease (creatinine clearance < 30 mL/min). This indicates a risk of increased systemic exposure in the context of impaired renal function.

Connection to the overall interaction profile

The overall profile is defined primarily by specific pharmacodynamic restrictions involving other immunomodulators and vaccines, which result in formal regulatory warnings against co-administration. Separately, the profile contains an important pharmacokinetic consideration based on the medicine's route of elimination, documenting that renal impairment substantially decreases clearance and increases systemic exposure.

Mechanism of Action

The mechanism of action for Kineret (Anakinra) is a highly selective blockade of the Interleukin-1 ( IL-1) signaling pathway. The drug functions as a competitive receptor antagonist, disrupting the core mechanistic driver of systemic inflammation.

Selective Competitive Receptor Antagonism

Kineret is a recombinant version of the naturally occurring human IL-1 Receptor Antagonist ( IL-1Ra). It exerts its effect by binding directly to the Interleukin-1 Type I Receptor ( IL-1R1). This physical interaction competitively prevents the binding of the pro-inflammatory cytokines, IL-1alpha and IL-1beta. This occupancy functionally sequesters the receptor, and this action initiates or suppresses signaling sequences that produce defined downstream effects.

Dampening the IL-1-Driven Inflammatory Cascade

The blockade of the IL-1R1 interrupts the intracellular IL-1 signal transduction pathway. This modifies early molecular steps that influence subsequent systemic physiological responses. By interrupting this upstream signal, the mechanism reduces the magnitude of IL-1-dependent mediator activity and dampens IL-1-driven components of the acute-phase response. This contributes to reducing the magnitude of dysregulated pathway activity.

Modulating Pro-Catabolic Signaling

The drug engages mechanisms that regulate overactive processes, particularly at the tissue level. IL-1 signaling drives pro-catabolic activity in structural cells. Kineret's selective IL-1 blockade modulates the signaling patterns that control these processes, resulting in the preservation of tissue homeostasis within IL-1-affected pathways.

Dosage and Administration Information

Kineret (anakinra) is administered as a daily subcutaneous injection using a prefilled, single-use syringe. The specific dosage and frequency are determined by a healthcare provider based on the condition being treated and the patient's weight or kidney function.

Dosage Guidelines

Indication	Standard Recommended Dose	Dose Adjustment Considerations
Rheumatoid Arthritis (RA) (Adults)	100 mg daily	Consider 100 mg every other day for patients with severe renal impairment (creatinine clearance < 30 mL/min).
NOMID/DIRA (Adults and Children)	Starting dose is 1–2 mg/kg daily; can be adjusted up to 8 mg/kg daily.	Consider administration every other day for patients with severe renal impairment.

Injection and Storage

To ensure proper administration, patients or caregivers should receive comprehensive training from a healthcare professional. The injection should be given at approximately the same time each day.

Preparation: Kineret must be stored in the refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze or shake. The prefilled syringe should be removed from the refrigerator and allowed to warm to room temperature for about 30 minutes before injecting. Inspect the solution to ensure it is clear and colorless; do not use the syringe if the liquid is cloudy, discolored, or contains large particulate matter.
Site Rotation: Inject into the abdomen (excluding the area around the navel) or the front of the middle thighs. It is essential to rotate injection sites to prevent injection site reactions such as redness, swelling, or pain. Do not inject into skin that is tender, bruised, hard, or scarred.
Disposal: After injection, the used prefilled syringe should be placed immediately into a puncture-resistant sharps disposal container.

Recent Clinical Evidence

Research evidence / Overview of studies for Kineret

Evidence for use in Rheumatoid Arthritis (RA)

Research has explored the use of Kineret in adults with Rheumatoid Arthritis (RA), a condition marked by functional limitations and outcomes related to physical discomfort in the joints. The main body of evidence comes from Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and how patients reported their experiences over a defined, short-term interval. Studies monitored patient-reported outcomes describing perceived discomfort, functional status, and changes in joint stiffness and swelling. Research examined changes measured during the study period and reported patterns observed in the studied populations with active RA.

Evidence for use in Rare Autoinflammatory Syndromes (CAPS and DIRA)

Kineret was observed in research for conditions characterized by fluctuating or episodic manifestations, specifically Cryopyrin-Associated Periodic Syndromes (CAPS) and Deficiency of IL-1 Receptor Antagonist (DIRA). Because these are very rare conditions, studies exploring short-term symptom changes in these groups necessarily involved modest sample sizes. Research focused on episodes where symptoms become more noticeable, such as fever, rash, and outcomes linked to inflammatory or irritative states. Studies report how symptoms evolved in the observed populations, with findings describing patterns related to changes in the severity of episodic symptoms in both children and adults.

What Research Gaps and Uncertainties Remain

While Kineret was observed in research for these conditions, the research highlights areas where the evidence is not yet complete. Specifically, comparative evidence is lacking, meaning there are few head-to-head trials comparing Kineret directly against all other treatment options. Furthermore, sample sizes were modest for the rare disease indications, and there is limited information for long-term outcomes, particularly regarding outcomes measured years after the initial research. Certainty remains low in areas where data for certain groups (like those with multiple co-existing medical conditions) remain insufficient.

Key Studies & References KINERET® (anakinra) Official HCP Website | DIRA Efficacy (References DIRA and CAPS long-term studies)

Frequently Asked Questions (FAQ)

Common questions about Kineret (FAQ)

Q: How long does it usually take to notice an improvement in symptoms after starting Kineret?

Studies and official information indicate that for conditions like rheumatoid arthritis (RA), the onset of the effect has been observed within the first two weeks of beginning treatment. For certain auto-inflammatory syndromes, some patients may experience a rapid response.

Q: Is it possible for Kineret to stop working after a period of time?

Clinical trials for conditions like rheumatoid arthritis and CAPS have generally found that the safety and efficacy profile remains unchanged during long-term treatment. Regulatory documents do not specifically address the concept of a medicine losing its effect over time. Monitoring by a healthcare provider is part of ongoing treatment.

Q: Are injection site reactions (redness, itching, swelling) with Kineret considered normal, and how long do they typically last?

Injection site reactions, such as redness, pain, or swelling, are considered very common side effects, according to official product information. These reactions are typically mild and often occur most frequently at the beginning of treatment. They generally resolve within 14 to 28 days.

Q: What are some ways to minimize the burning or stinging sensation of the Kineret injection?

The drug is supplied cold, and official administration instructions recommend that the pre-filled syringe be removed from the refrigerator and allowed to warm naturally to room temperature for about 30 minutes before injection. This procedure is intended to reduce the potential for discomfort upon administration.

Q: What should I do if I accidentally miss a daily dose of Kineret?

If a dose is missed, patients should contact their healthcare provider as soon as possible for guidance on when to take the next injection. Official guidance warns against taking two doses to make up for a missed one.

Q: How long does the active substance in Kineret, anakinra, stay in the body?

According to official pharmacokinetic studies, the terminal half-life of anakinra (the active substance) in patients with rheumatoid arthritis is approximately 4 to 6 hours.

Q: What information is available regarding the long-term safety of Kineret?

Official information indicates that the safety profile has been observed to generally remain unchanged over long-term treatment for approved indications. Monitoring of progress and blood counts by a healthcare provider is typically required during long-term treatment.

Q: What is the typical amount of time Kineret is allowed to warm up before injection?

The pre-filled syringe should be removed from the refrigerator and allowed to warm to room temperature (up to 25 C) for approximately 30 minutes before injection. It is important to note that once the syringe has reached room temperature, it must not be placed back in the refrigerator.

Q: Is it better to inject Kineret in the morning or the evening?

Regulatory documents state that Kineret should be administered at approximately the same time every day to maintain consistent levels of the medicine in your system. However, regulatory documents do not specify a particular time of day (morning or evening).

Q: Is it normal to feel a hard lump or swelling at the injection site a day after the shot?

Injection site reactions, including swelling (edema) and induration (a hardened area or lump), are listed as very common side effects in the official product labeling. This is considered a temporary, localized response to the injection.

Q: What is the main difference between Kineret and other biologic medicines for rheumatoid arthritis?

Kineret is classified as an Interleukin-1 (IL-1) inhibitor, meaning its mechanism of action is focused on blocking the IL-1 protein, a key driver of inflammation. This differs from many other biologics, such as TNF blockers, which target different inflammatory pathways.

Q: Is a headache a common side effect of starting Kineret treatment?

Headache is listed as a very common adverse reaction in certain patient populations from clinical studies. While its frequency specifically at the start of treatment is not detailed, it is one of the commonly reported effects overall.

Q: Does Kineret increase the overall risk of getting infections like a cold or the flu?

Clinical trials reported that Upper Respiratory Tract Infections (such as the common cold) and flu-like symptoms are listed as common side effects. Patients should remain vigilant for signs of any infection, especially serious ones.

Q: What research or clinical evidence supports the use of Kineret for NOMID (Neonatal-Onset Multisystem Inflammatory Disease)?

Kineret is officially approved by the FDA for the treatment of NOMID, which is the most severe form of Cryopyrin-Associated Periodic Syndromes (CAPS). The FDA label includes specific data from clinical studies conducted for this rare disease indication.

Q: Why is Kineret sometimes referred to by its generic name, anakinra?

Anakinra is the official generic name, also known as the International Nonproprietary Name (INN), for the active ingredient in the medicine. Kineret is the brand name used by the manufacturer.

Q: Does Kineret have known interactions with common over-the-counter pain relievers?

Regulatory information explicitly states that no formal drug interaction studies have been conducted with many commonly used medicines, including those such as non-prohibited over-the-counter pain relievers. You should always discuss all medications you take with your healthcare provider.

Q: What parts of the body are the most common and safest injection sites for Kineret?

The recommended injection sites, according to administration instructions, are the fatty areas of the abdomen (excluding the area around the navel) and the front of the middle thighs. It is important to rotate injection sites with each daily injection.

Q: Is Kineret a drug that suppresses the entire immune system, or is it more targeted?

Kineret is a highly targeted biologic agent, classified as an Interleukin-1 (IL-1) inhibitor. It works by selectively blocking the IL-1 signaling pathway, making it more focused than drugs that suppress the immune system broadly.

Q: Does Kineret interact with common herbal supplements or vitamins?

Official regulatory documents do not contain any formal studies or specific warnings regarding interactions between Kineret and common herbal supplements or vitamins. Patients are generally advised to inform their healthcare provider about all supplements they are taking.

Q: Can Kineret cause joint pain or a worsening of rheumatoid arthritis symptoms initially?

Clinical studies in patients with rheumatoid arthritis have listed both worsening of rheumatoid arthritis symptoms and arthralgia (joint pain) as common adverse reactions. You should discuss any changes in symptoms with your healthcare provider.

Q: What information exists about the use of Kineret in older adult populations?

Official guidelines note that because the elderly population (age 65 and over) typically has a higher incidence of infections overall, extra caution should be exercised when Kineret is administered to older patients.

Q: Why is Kineret sometimes mentioned in the context of treating COVID-19?

Kineret has received specific authorization from the European Medicines Agency (EMA) for treating COVID-19 in adults with pneumonia who require supplemental oxygen and are at risk of severe respiratory failure. The FDA has also issued an Emergency Use Authorization (EUA) for this purpose.

How should Kineret be stored and disposed of?

Storage and Disposal Requirements for Kineret (Anakinra)

The medicine must be stored continuously under refrigeration at a temperature between 2 C and 8 C (36 F and 46 F). Kineret must be kept in its original carton to protect it from light and must not be frozen or shaken.

Stability and Handling

If the prefilled syringe is removed from the refrigerator, it can be kept at room temperature, up to 25 C, for a maximum of 72 hours. Once the syringe has reached room temperature, it must not be placed back in the refrigerator and must be discarded if unused after 72 hours. Keep Kineret out of the reach of children.

Disposal

The Kineret prefilled syringe is for single use. Used syringes and needles must be placed immediately into a puncture-resistant sharps disposal container. Any unused product or waste material must be disposed of in accordance with local regulations.

Kineret